Analysts expect that DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Get Rating) will post ($0.16) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for DiaMedica Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.16) and the highest estimate coming in at ($0.15). DiaMedica Therapeutics posted earnings of ($0.17) per share during the same quarter last year, which would indicate a positive year over year growth rate of 5.9%. The company is scheduled to announce its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that DiaMedica Therapeutics will report full year earnings of ($0.68) per share for the current year, with EPS estimates ranging from ($0.71) to ($0.64). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover DiaMedica Therapeutics.
DiaMedica Therapeutics (NASDAQ:DMAC – Get Rating) last posted its earnings results on Wednesday, May 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.07. During the same period in the previous year, the company posted ($0.19) EPS.
Shares of NASDAQ:DMAC traded down $0.06 during trading on Monday, hitting $2.44. 119,287 shares of the company were exchanged, compared to its average volume of 52,333. The stock has a 50 day moving average of $2.47 and a 200 day moving average of $3.08. DiaMedica Therapeutics has a 52-week low of $2.12 and a 52-week high of $9.55.
Several hedge funds have recently modified their holdings of DMAC. Morgan Stanley raised its position in shares of DiaMedica Therapeutics by 21.6% in the second quarter. Morgan Stanley now owns 23,627 shares of the company’s stock worth $105,000 after buying an additional 4,202 shares in the last quarter. Geode Capital Management LLC raised its position in shares of DiaMedica Therapeutics by 25.6% in the third quarter. Geode Capital Management LLC now owns 167,763 shares of the company’s stock worth $672,000 after buying an additional 34,194 shares in the last quarter. Jump Financial LLC purchased a new stake in shares of DiaMedica Therapeutics in the third quarter worth $73,000. Two Sigma Investments LP bought a new position in DiaMedica Therapeutics in the third quarter valued at $298,000. Finally, Two Sigma Advisers LP increased its stake in DiaMedica Therapeutics by 529.7% in the third quarter. Two Sigma Advisers LP now owns 80,600 shares of the company’s stock valued at $323,000 after acquiring an additional 67,800 shares during the last quarter. Institutional investors own 19.16% of the company’s stock.
DiaMedica Therapeutics Company Profile (Get Rating)
DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke.
- Get a free copy of the StockNews.com research report on DiaMedica Therapeutics (DMAC)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.